ERBB2 and non-small cell lung carcinoma: Recently several anti-HER2 drugs have been assessed for patients with NSCLC [6]; the anti-HER2 antibody–drug conjugate trastuzumab–deruxtecan received FDA approval for NSCLC harboring HER2 mutations [20].